Cargando…
Analysis of peginterferon β-1a exposure and Gd-enhanced lesion or T2 lesion response in relapsing-remitting multiple sclerosis patients
The effect of subcutaneous (SC) peginterferon β-1a exposure on reduction of gadolinium-enhanced (Gd+) lesion count over time was evaluated in patients with relapsing-remitting multiple sclerosis (RRMS) in a Phase 3 study (ADVANCE). Patients were randomized to receive SC injections of placebo (n = 50...
Autores principales: | Hang, Yaming, Hu, Xiao, Zhang, Jie, Liu, Shifang, Deykin, Aaron, Nestorov, Ivan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4954841/ https://www.ncbi.nlm.nih.gov/pubmed/27299457 http://dx.doi.org/10.1007/s10928-016-9477-x |
Ejemplares similares
-
Population‐Based Pharmacokinetic and Exposure‐Efficacy Analyses of Peginterferon Beta‐1a in Patients With Relapsing Multiple Sclerosis
por: Hu, Xiao, et al.
Publicado: (2017) -
Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsingremitting multiple sclerosis in the randomized ADVANCE study
por: Hu, Xiao, et al.
Publicado: (2015) -
Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis
por: Arnold, Douglas L, et al.
Publicado: (2014) -
Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis
por: Newsome, Scott D., et al.
Publicado: (2016) -
Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE
por: Kieseier, Bernd C, et al.
Publicado: (2015)